Sermorelin in the US: GHRH(1-29), and the Approval That Was Withdrawn

Sermorelin is the first 29 residues of human growth-hormone-releasing hormone, amidated at the C-terminus. That fragment was established early in the GHRH literature as the shortest sequence retaining full biological activity at the GHRH receptor, which is why every subsequent GHRH analog in the catalog is built on it or on the full 44-residue sequence.

The parent hormone was characterized by Guillemin and colleagues in 1982, isolated from a pancreatic tumour that had caused acromegaly, which remains one of the cleaner discovery stories in endocrinology.[3] Sermorelin acts on pituitary somatotrophs to stimulate endogenous GH release, leaving the pituitary's own feedback regulation in place.

Research Material

Twenty-nine residues, around 3358 Da, C-terminally amidated, with no acylation and no non-natural residues. The absence of a stabilizing modification is the defining practical difference between sermorelin and tesamorelin: sermorelin is cleaved rapidly by DPP-4 at the N-terminus, giving a half-life measured in minutes.

The amidation is a quality attribute worth checking. A free-acid C-terminus differs by 1 Da from the amide and has reduced activity, and the difference is resolvable by mass spectrometry and invisible on a purity trace.

Amino Acid Sequence

Chemical Structure

A well-characterized compound with a review literature rather than a trial pipeline:

• ·Discovery of the parent hormone. Guillemin et al., Science 1982: isolation and characterization of growth hormone-releasing factor from a human pancreatic tumour causing acromegaly.[3]
• ·Clinical review, paediatric use. Prakash and Goa (1999) review sermorelin's use in diagnosis and treatment of children with idiopathic growth hormone deficiency, which is the indication its approval covered.[1]
• ·Adult-onset context. Walker (2006) discusses sermorelin in adult-onset growth hormone insufficiency and the pharmacological argument for stimulating endogenous secretion rather than replacing GH.[2]

Sermorelin's marketing authorization was discontinued, and the compound is not currently an approved product in the US. A lapsed approval is a commercial fact, not a safety endorsement and not a current authorization. Material bought as a research chemical is not the discontinued product and does not inherit its regulatory status.

Beyond the paediatric diagnostic and treatment context its approval covered, sermorelin has no established indication, no current approval anywhere, and no modern randomized evidence base. the FDA has authorized nothing containing it today.

Identity by mass spectrometry against the expected mass near 3358 Da, HPLC purity, and measured content against the labeled amount. Ask specifically whether the identity report is consistent with the C-terminal amide rather than the free acid; on a 29-residue peptide the 1 Da difference is well within the resolving power of the instruments used and is worth confirming.

Every Eppix sermorelin lot is tested by Janoshik Analytical, published before sale and verifiable on the laboratory's own database.

Published Certificate

Batch

SERM-CA-26D-01

Purity (HPLC)

Not reported

Measured content

Not reported

Laboratory

Not reported

Verify on the lab’s own databaseAll published certificates

Domestic fulfillment is by FedEx, typically one to three business days across the United States, free over $200 USD, with card and PayPal checkout and mix-and-match pricing at 5 and 10 vials.

The other GHRH-axis guides are buy tesamorelin in the US and buy CJC-1295 and ipamorelin in the US.

Available at Eppix Labs

Sermorelin

5mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $39.99 USDIn stock